With a market capitalization (market cap) of $4.86B — a measure of how much the company is worth — Dyne Therapeutics, Inc. is the 1449th most valuable company in Healthcare as of August 18, 2026. Shares trade at $26.00, down +0.57% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Visit websiteAs of August 18, 2026, Dyne Therapeutics, Inc. (DYN) is worth $4.86B — this is its market capitalization, the total value of all its outstanding shares.
Dyne Therapeutics, Inc.’s market cap is $4.86B, which ranks it #1449 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Dyne Therapeutics, Inc. (DYN) shares trade at $26.00, down 0.57% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025